Iberdomide Regimen Cuts RRMM Progression Risk by 51%, Trial Finds
Bristol Myers Squibb's iberdomide (Zenbexus) with daratumumab and dexamethasone (ZDd) showed a 51% reduction in disease progression risk vs standard treatment in a phase 3 trial. Median PFS was 42 months with ZDd vs 20 months with DVd. The FDA approved ZDd for RRMM in August 2026 based on earlier MRD-negative CR results. Full trial results will be presented in 2026.
How this was made
The 30-second read
Why it matters
The trial met its primary endpoints, showing a median PFS of 42 months vs 20 months and a 51% risk reduction, leading to accelerated FDA approval on Aug 13 2026.
Market read
The data provide a new, effective therapy for relapsed/refractory multiple myeloma, likely driving BMY stock higher and influencing the broader oncology biotech sector.
What to watch
Reimbursement and pricing negotiations may affect commercial uptake
Background
The EXCALIBER‑RRMM Phase 3 trial compared iberdomide + daratumumab + dexamethasone (ZDd) versus standard daratumumab + bortezomib + dexamethasone (DVd) in 800 RRMM patients.
Ticker impact
Bristol Myers Squibb announced positive Phase 3 trial results for its iberdomide regimen (ZDd) in RRMM, showing a 51% reduction in progression risk and accelerated FDA approval.
likely upward pressure as investors price in the new therapy's market potential
The data represent a material clinical breakthrough for a listed biotech, with immediate commercial implications and a recent regulatory approval.
Market effects
strengthens the multiple‑myeloma therapeutic space and may lift peer biotech stocks
U.S. biotech sector gains
global oncology market sees new treatment option
Counterpoint
Potential safety concerns from high neutropenia rates could temper enthusiasm
Key entities
- CompanyBristol Myers Squibb
US‑listed pharmaceutical company developing iberdomide (Zenbexus).
- DrugIberdomide (Zenbexus)
Oral immunomodulatory agent evaluated in RRMM.
